RenovoRxRNXT
Market Cap: $23.6M
About: RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.
Employees: 8
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
700% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 1
300% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 1
129% more capital invested
Capital invested by funds: $442K [Q1] → $1.01M (+$570K) [Q2]
70% more funds holding
Funds holding: 10 [Q1] → 17 (+7) [Q2]
0.65% more ownership
Funds ownership: 3.08% [Q1] → 3.74% (+0.65%) [Q2]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
Ascendiant Capital Edward Woo 43% 1-year accuracy 20 / 47 met price target | 739%upside $8.25 | Buy Maintained | 12 Sept 2024 |